https://scholars.lib.ntu.edu.tw/handle/123456789/641586
標題: | Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study | 作者: | Verstovsek, Srdan Gerds, Aaron T Vannucchi, Alessandro M Al-Ali, Haifa Kathrin Lavie, David Kuykendall, Andrew T Grosicki, Sebastian Iurlo, Alessandra Goh, Yeow Tee Lazaroiu, Mihaela C Egyed, Miklos Fox, Maria Laura McLornan, Donal Perkins, Andrew Yoon, Sung-Soo Gupta, Vikas Kiladjian, Jean-Jacques Granacher, Nikki Lee, Sung-Eun Ocroteala, Luminita Passamonti, Francesco Harrison, Claire N Klencke, Barbara J Ro, Sunhee Donahue, Rafe Kawashima, Jun Mesa, Ruben HSIN-AN HOU |
公開日期: | 28-一月-2023 | 卷: | 401 | 期: | 10373 | 起(迄)頁: | 269 | 來源出版物: | Lancet (London, England) | 摘要: | Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and JAK2, has shown symptom, spleen, and anaemia benefits in myelofibrosis. We aimed to confirm the differentiated clinical benefits of momelotinib versus the active comparator danazol in JAK-inhibitor-exposed, symptomatic patients with anaemia and intermediate-risk or high-risk myelofibrosis. |
URI: | https://www.scopus.com/record/display.uri?eid=2-s2.0-85147076327&doi=10.1016%2fS0140-6736%2822%2902036-0&origin=inward&txGid=33344ffad11a0508646e14de68161342 https://scholars.lib.ntu.edu.tw/handle/123456789/641586 |
ISSN: | 01406736 | DOI: | 10.1016/S0140-6736(22)02036-0 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。